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This study was designed to compare the eects of low-dose inhaled fluticasone propionate (100 mcg twice daily)
with those of the leukotriene antagonist, zafirlukast (20 mg twice daily), on bronchial hyper-responsiveness. The
study recruited 30 patients (nine men, 21 women; mean age 45 years) with forced expiratory volume in 1 sec (FEV1)
>50% and airway reversibility to salbutamol 15%. This was a single centre, double-blind, double-dummy cross-
over study, composed of two successive 2-week treatment periods, each preceded by a 2–4 week single-blind placebo
period. Following 2 weeks of treatment with fluticasone propionate and zafirlukast, the mean provocational
concentration causing a 20% fall in FEV1 (PC20) histamine was 1?61 mg ml
71 (SD 2?34) and 0?99 mg ml71 (SD 1?74)
respectively. Taking baseline dierences into account, the dierence between treatments was equivalent to 0?77
doubling doses of histamine (95% CI, 0?05–1?50; P=0?037). Morning peak flow values were significantly higher
(17 l min71; P=0?049) after treatment with fluticasone propionate during the second week of treatment. Both
treatments were well tolerated. The results of this short-term study show that compared with zafirlukast, a low dose
of fluticasone propionate oers greater clinical benefit and is more cost eective.
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Fluticasone propionate, an inhaled corticosteroid estab-
lished in the treatment of asthma, has been shown to benefit
from an improved ecacy to safety ratio when compared
with other inhaled steroids. Studies in both adults and
children assessing lung function, symptoms and extra
bronchodilator usage have shown that fluticasone propio-
nate is more eective than beclomethasone dipropionate
(1–3) or budesonide (1,4,5) when used at half the dose of
these inhaled corticosteroids. When used in chronic
treatment, fluticasone propionate at doses of 750 mcg
day71 and above have been shown to be very eective in
decreasing bronchial hyper-responsiveness (6–8). Its e-
cacy in this respect was achieved at half the dose of
beclomethasone dipropionate (8).Received 22 October 1998 and accepted in revised form 11 May
1999.
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0954-6111/00/020112+07 $35?00/0Although many mediators are involved in the patho-
genesis of asthma, there is evidence to suggest that cysteinyl
leukotrienes are important mediators of the asthmatic
response (9). A number of studies have demonstrated that
leukotrienes are potent bronchoconstrictors (10) as well as
inducers of mucus hypersecretion (11) and airway oedema
(12). It has been shown that the urinary leukotriene
E4 (LTE4), used as a marker for whole body cysteinyl
leukotriene production, increases following allergen chal-
lenge (13) and during acute asthma attacks (14). However,
no correlation has been found between the severity of
clinical asthma and the level of LTE4 in the urine of stable
asthmatic patients (15).
Several placebo-controlled studies have demonstrated
that chronic treatment with leukotriene antagonists results
in decreased asthmatic symptoms, improved lung function
and decreased use of bronchodilator (16–19) with measur-
able eects being achieved within 3–14 days of therapy (19).
Leukotriene receptor antagonists, as well as drugs which
interfere with leukotriene formation, have been shown to
attenuate the obstructive response induced by cold, dry air
hyperventilation, exercise, allergen and aspirin (20–22).# 2000 HARCOURT PUBLISHERS LTD
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the bronchial hyper-responsiveness provoked by pharma-
cological stimuli (23–25). It has been proposed, therefore,
that leukotriene antagonists may constitute alternative first-
line preventative therapy for patients with mild to moderate
asthma who are receiving intermittent inhaled 2-agonist
therapy (26). However, there are very few comparative data
to support this proposal.
Asthma is characterized by reversible airways obstruction,
oedema and inflammation as well as hyper-responsiveness
to provocative stimuli. Non-specific bronchoconstrictor
stimuli such as histamine and methacholine are widely
used to demonstrate bronchial hyper-responsiveness. The
provocative concentration (PC20 histamine) producing a
20% fall in forced expiratory volume in 1 sec (FEV1) is used
as a measure of sensitivity. This is lowered in asthmatics
(27). This study was designed to compare the eects on
bronchial hyper-responsiveness of 2 weeks’ treatment with
low-dose fluticasone propionate (100 mcg twice daily) and
the leukotriene antagonist, zafirlukast (20 mg twice daily)
respectively. Bronchial hyper-responsiveness was assessed
by histamine provocation.
Methods
SUBJECTS
Non-smoking, adult patients aged 18–70 years with a
documented clinical history of reversible airways disease
were recruited into the study. None of the patients had used
oral or inhaled coricosteroids, sodium cromoglycate,
nedocromil or long-acting b2-agonists for at least 4 weeks
before the start of the study. Other entry criteria,
established during the run-in period, included: FEV1 of at
least 50% of predicted normal value; reversibility of airway
obstruction of at least 15% following 200 mcg salbutamol
from a metered dose inhaler (MDI) or 400 mcg salbutamol
from a Diskhaler inhaler; and PC20 histamine 4 mg ml71
Patients were excluded from the study if they had been
admitted to hospital with asthma or had received anti-
biotics for an upper or lower respiratory tract infection
within the previous month. Other exclusion criteria
included: ketotifen therapy within the previous 3 months;
lactation, pregnancy or inadequate contraceptive precau-
tions in women of child-bearing potential; inadequate
inhaler and peak flow meter techniques. Approval was
obtained from the local research ethics committee and all
patients provided their written informed consent.
STUDY DESIGN
This was a randomized, double dummy, cross-over study;
patients were recruited from two hospital centres. Initially,
patients entered a 2–4 week, single-blind, placebo run-in
period. During this period all asthma medication (apart
from regular methylxanthines and anticholinergics) was
replaced by inhaled salbutamol from a Diskhaler inhaler
or MDI, which was to be used as necessary to relieve
symptoms. Therapy for all other medical conditions was toremain constant throughout the study. Patients who
fulfilled the eligibility criteria were then randomly assigned
to 2 weeks’ double-blind treatment (treatment period 1)
with either inhaled fluticasone propionate 100 mcg twice
a day (b.d.) administered by Diskhaler inhaler or oral
zafirlukast 20 mg b.d. Thereafter, patients entered a 2–4
week single-blind, wash-out period on placebo followed by
a subsequent 2-week period where, again under double-
blind conditions, they received the alternative active
treatment (treatment period 2). Patients were instructed to
use their medication in the morning (around 0800 h) and in
the evening (around 2000 h).
Assessments were performed in the clinic at the beginning
and end of the placebo run-in period, at the end of
treatment period 1, after the placebo washout period and at
the end of treatment period 2.
At the first clinic visit, demographic details and a full
clinical history were recorded and a physical examination
was performed. Investigators also confirmed that patients
could use an inhaler and a peak flow meter correctly. In
addition, FEV1 was measured using a spirometer and the
highest of three values was recorded. At the beginning or
end of the run-in period, airway reversibility was deter-
mined by recording FEV1 before and 15 min after the
inhalation of 200 mcg salbutamol from a MDI or 400 mcg
salbutamol via Diskhaler inhaler. Histamine challenge tests
were also performed at the end of the run-in period, at the
end of treatment period 1 and at the end of treatment
period 2 on separate days to the pulmonary function
tests, but within 3 successive days. All pulmonary function
and airway challenge tests were performed at 0900 h
(1 h), patients were therefore requested not to use their
bronchodilators for at least 4 h before each clinic visit.
Baseline lung function was recorded as the best of three
reproducible values of FEV1 (within 5%) before the
provocation tests. The histamine provocation test was
performed according to the method of Cockcroft et al. (28).
Aerosols of histamine were generated by a jet nebuliser with
a fixed output of 0?13 ml min71. A nose clip was worn and
the aerosol was inhaled by tidal breathing for 30 sec. The
first aerosol was saline and was followed at 5-min intervals
by doubling concentrations of histamine (0?125–32 mg ml).
FEV1 was measured before and 1 min after each
inhalation until the reading had fallen by 20% or more
from the lowest post-saline value. The results were
expressed as PC20 histamine. The exact value for PC20
histamine was determined in mg ml71 by linear interpola-
tion of the last two points of the concentration–response
curve
All patients kept daily record cards throughout the study,
recording morning and evening peak expiratory
flow (PEF), study medication, use of relief medication
and symptoms by day and by night. Symptoms related to
daily activities were rated as follows: 0 = none; 1 =
symptoms for one short period; 2 = symptoms for two or
more short periods; 3 = symptoms for most of the day
which did not aect your normal daily activities; 4 =
symptoms for most of the day which did aect your normal
daily activities; 5 = symptoms so severe that you could not
perform normal daily activities. Symptoms during the night
114 J. WESTBROEK AND H. R. PASMArelated to sleep disturbance and were rated as follows: 0 =
none; 1 = symptoms caused you to wake once or wake
early; 2 = symptoms caused you to wake twice or more
(including waking early); 3 = symptoms caused you to be
awake for most of the night; 4 = symptoms so severe that
you did not sleep at all. Patients were also requested to
record the number of times salbutamol was required for
symptomatic relief both during the day and at night.
At the beginning and end of the treatment period, blood
samples were taken for routine haematology and biochem-
istry. In addition, the oropharynx was examined at each
clinic visit and a swab was taken if clinically indicated to
determine the presence of Candida spp.
STATISTICAL ANALYSIS
The level of significance for all analyses was 5%, all tests
were two-sided and all were based on the intention-to-treat
sample. Predicted lung function values were calculated
from sex, age and height using standard formulae (29).
The primary measure of ecacy was PC20 histamine
values. Only patients who provided data for both treatment
periods were included in the statistical analysis. The
presence of carry-over eects was investigated using
Wilcoxon’s rank-sum test. Log-transformed PC20 values
were analysed by analysis of covariance (ANCOVA)
adjusting for study period, patient and pre-treatment value
(obtained at the start of each treatment period) as
covariates and treatment as main eect.
The daily morning/evening PEF values were averaged
over patients and plotted by treatment group. Baseline PEF
was established by taking the mean of the last 7 days of the
run-in period for each patient. Average weekly values (for
week 1 and week 2) were analysed using ANCOVA as
described for PC20 histamine values and the presence of
carry-over eects was investigated using Wilcoxon’s rank-
sum test. No formal analysis was applied to symptom score
data and the use of rescue bronchodilator medication.
It was estimated that 30 evaluable patients would provide
90% power to detect a treatment dierence of at least 0?7
doubling doses of histamine with a 5% level of significance.
This assumed a within-patient standard deviation of up to
0?75 of a doubling dose.
Results
Of the 30 patients who completed the placebo run-in
period, the majority were women. Seventy-seven percent
were atopic (diagnosed by skin test) and 80% had been
suering from asthma for over 6 years. There were no
significant dierences in baseline characteristics between the
two treatment sequence groups (Table 1). The mean PC20
values prior to treatment were similar in both groups (0?57
mg ml71 for fluticasone propionate; 0?58 mg ml71 for
zafirlukast). Only one patient was receiving concurrent
anticholinergic therapy and none were receiving methyl-
xanthines. Three patients were withdrawn from the study,
two because of adverse events and one because incorrectmedication was taken during the wash-out period. The
remaining 27 patients completed the study.
BRONCHIAL HYPER-RESPONSIVENESS
Baseline FEV1 values taken before histamine challenges did
not dier significantly between active treatment groups.
Pre-saline FEV1 values before treatment were 2?52 0?7 l
and 2?0  0?69 l, for the fluticasone propionate (n=29) and
zafirlukast (n=30) groups, respectively, and post-saline
values were 2?55  0?9l and 2?49  0?67 l.
There was no evidence of carry-over with respect to PC20
(P=0?289) and all data were therefore combined. At the
start of treatment PC20 values were similar for both
treatment groups. (Table 1, Fig. 1). The change in reac-
tivity, however, after 2 weeks’ treatment with each agent,
was significantly dierent: the mean PC20 histamine was
1.61 mg ml71 (SD 2?34) after treatment with fluticasone
propionate, compared with 0?99 mg ml71 (SD 1?74) after
treatment with zafirlukast (Fig. 1). Using ANCOVA where
period, patient and baseline were used as covariants, this
dierence was equivalent to 0?77 doubling doses of
histamine (95% CI, 0?05–1?50; P=0?037).
DAILY RECORD CARD DATA
Mean morning and evening PEF values tended to be higher
in the fluticasone propionate group than in the zafirlukast
group both during the first and second week of treatment.
Mean morning peak flow is shown in Fig. 2. A significant
treatment dierence (17?7 l min71; P=0?049) was observed
in morning PEF values during the second week (Table 2).
The majority of patients had no symptoms or suered
from very mild symptoms throughout the study. They used
very little extra relief bronchodilator and no obvious
dierences were detected between the two treatments.
ADVERSE EVENTS
No serious adverse events were reported during the study.
Overall, nine patients reported 14 adverse events; six
patients reported 10 adverse events during treatment with
fluticasone propionate and three patients reported four
adverse events during treatment with zafirlukast. Only one
event (asthma attack during zafirlukast therapy) was judged
to be related to study medication. During treatment with
fluticasone propionate, there were three reports of head-
ache, two of common cold and one report each of back
pain, diabetes, dizziness, ear infection and fatigue. Further
investigation into the report of ‘diabetes’ revealed that this
patient had elevated blood glucose levels prior to the study.
This event therefore, bears no relation to study treatment.
During treatment with zafirlukast, there was one report
each of headache, asthmatic attack, fever and pyrosis. Two
patients were withdrawn from the study during wash-out
periods, one following fluticasone propionate treatment
(dyspnoea), the other following zafirlukast treatment
(dyspnoea plus chest pains).
TABLE 1. Baseline patient characteristics
FP
followed by
zafirlukast
(n=15)
Zafirlukast
followed by
FP
(n=15)
Total
(n=30)
Sex M/F 4/11 5/10 9/21
Age (years)
Mean (SD) 46 (17) 44 (14) 45 (15)
Atopic, n (%) 13 (87%) 10 (67%) 23 (77%)
Duration of asthma (years)
51 1 1 2
1–5 2 2 4
46 12 12 24
FEV1
% predicted FEV1 mean (SD) – – 77(14)*
Before FP (l) mean (SD) 2?52 (0?7)
Before zafirlukast (l) mean (SD) – – 2?50 (0?69)
PC20 histamine (mg ml
71)
Before FP mean (SD) – – 0?57 (0?93)**
Before zafirlukast mean (SD) – – 0?58 (0?91)
FP fluticasone propionate.
*n=22; **n=29.
Not calculated.
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aspartate aminotransferase (AST, SGOT), alanine amino-
transferase (ALT, SGPT) and gamma glutamyltransferase
(GGT). No trends were apparent from the summary data
and none of the changes recorded was judged to be clinically
significant. Apart from one patient who had an abnormal
oropharyngeal throat examination at one visit, all throat
examinations from all patients were normal. The physician
did not, however, recommend further investigation.
Discussion
The results of this study showed that, after 2 weeks’
therapy, inhaled fluticasone propionate 100 mcg b.d.FIG 1. The change in reactivity (mean PC20) following 2
weeks of treatment with zafirlukast and fluticasone
propionate.decreased bronchial hyper-responsiveness to a significantly
greater extent than oral zafirlukast 20 mg b.d. Lung
function also tended to improve more with fluticasone
propionate than with zafirlukast. There was a clinically
significant dierence between treatments (17?7 l min71) in
morning PEF during the second week of therapy, being
higher after treatment with fluticasone propionate.
The extent to which fluticasone propionate 100 mcg b.d.
reduced bronchial hyper-responsiveness in this study is
consistent with the results of a previous study involving
mild asthmatic subjects during which fluticasone propio-
nate 1000 mcg daily for 2 weeks improved PC20 histamine
by 1?3 doubling doses (6). The only study to have reported
the eects of chronic treatment with zafirlukast on
bronchial hyper-responsiveness showed that by comparison
with placebo, zafirlukast 20 mg b.d. for 2 weeks was
associated with a significant mean shift in log PC20
methacholine of 0?38 log dose units and that PC20
methacholine was on average 2?5 times higher during active
treatment than during placebo treatment (23).
Two other studies have examined bronchial hyper-
responsiveness after a period of treatment with a leuko-
triene antagonist. The first was a double-blind, cross-over
study which observed the eects of oral pranlukast 225 mg
b.d. in the treatment of 11 stable asthmatics (24). After 1
week of treatment, pranlukast produced a small but
significant improvement in bronchial hyper-responsiveness
(half of one doubling dose of methacholine). The second
study, in 11 subjects, found pranlukast 450 mg b.d. to be
associated with improved clinical symptoms as well as
improved histamine reactivity to bronchial challenge
performed 12 and 24 weeks post-treatment (25).
FIG. 2. Unadjusted daily mean morning peak flow (l min71) values during the placebo run-in period and wash-out periods
and through the 2-week treatment periods. The mean values shown at the start and end of the study (days 14, 40 and 42)
were taken from a reduced sample of patients since data were only available from those patients who had completed diary
cards on those days. (*: treatment group 1; &: treatment group 2; vertical lines represent the last day of a period.)
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bronchial hyper-responsiveness may vary depending on the
duration of the medication, short-term or single dose
studies failing to reflect the ultimate capability of anti-
leukotriene medication. That being the case, the acute
benefits of these drugs could not be assessed from bronchial
provocation using methacholine or histamine. The same
argument would apply in the case of inhaled corticoster-
oids, the degree of response being dependant on the severity
of disease, the dose, the duration of treatment and steroid
responsiveness of the patient. Indeed, it may be 12 months
before inhaled steroids exert their maximum eect on
bronchial reactivity (30).
While the pathogenesis of airway hyper-responsiveness is
unclear, in asthma it is linked with inflammation (31). In
stable asthmatic patients, airway responsiveness is relatedTABLE 2. Peak flow values (l min71)
FP
(n=29)
Zafirluka
(n=29)
Mean morning PEF*
1st week 396 390
2nd week 409 391{
Mean evening PEF*
1st week 412 400
2nd week 416 411{
*Means adjusted for period, patient and baseline (wher
to beginning treatment).
{n=28.
FP, fluticasone propionate.to the numbers of eosinophils and mast cells which are
present in bronchoalveolar lavage fluid (BAL), the extent of
mucosal inflammation and peripheral blood eosinophilia
(31). Eosinophils are one of the predominant inflammatory
cells in the asthmatic lung and they play a central role in
asthma (32). A correlation has been observed between
activated eosinophils and pulmonary function or non-
specific bronchial hyper-responsiveness (33–35). The docu-
mented eect of fluticasone propionate and zafirlukast on
eosinophils is therefore worthy of mention. In a placebo-
controlled, cross-over study involving 16 asthmatic pa-
tients, fluticasone propionate 500 mcg day71 taken over a
6-week period, significantly improved methacholine pro-
voked bronchial hyper-responsiveness and significantly
reduced both BAL eosinophil count and peripheral blood
eosinophil count (36). By comparison in another study,st Treatment
dierence
95% CI P value
6?1 74?7–16?9 0?256
17?7 70?08–35?3 0?049
12?0 72?1–26?0 0?091
5?4 77?9–18?6 0?412
e baseline is the average PEF during the week prior
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numbers of some of the inflammatory cells (basophils,
P50?01 and lymphocytes, P50?01) in BAL fluid following
segmental allergen challenge 5 days post-treatment, but to
have no eect on number of eosinophils and macrophages
(37). Pranlukast, however, has been observed to decrease
BAL macrophages, neutrophils and epithelial cells (38).
The comparative eects of inhaled corticosteroids and
leukotriene antagonists may account for their diering
capacity to reduce bronchial hyper-responsiveness.
The treatment of asthma focuses on diminishing the
inflammatory process and bronchial hyper-responsiveness.
Corticosteroids are by far the most eective and most
commonly used anti-inflammatory agents available (39).
Leukotrienes are just one of the many groups of mediators
involved in the complex inflammatory process leading to
the clinical manifestations of asthma. In this study we
found, even at a low dose and for a short treatment period,
that the eects of fluticasone propionate could be clearly
dierentiated from those of zafirlukast in mild asthma. This
present study suggests that the extent to which inhibiting
one set of inflammatory mediators can be expected to
attenuate the asthmatic response can be questioned. In
these patients, fluticasone propionate oers greater clinical
benefit than zafirlukast.
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